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Background/aim: To examine the effects of active and passive smoking on perioperative anesthetic and analgesic consumption.
Materials and methods: Patients were divided into three groups: group S, smokers; group PS, passive smokers; and group NS, individuals
who did not have a history of smoking and were not exposed to smoke. All patients underwent the standard total intravenous anesthesia
method. The primary endpoint of this study was determination of the total amount of propofol and remifentanil consumed.
Results: The amount of propofol used in induction of anesthesia was significantly higher in group S compared to groups PS and NS.
Moreover, the total consumption of propofol was significantly higher in group S compared to groups PS and NS. The total propofol
consumption of group PS was significantly higher than that of group NS (P = 0.00). Analysis of total remifentanil consumption showed
that remifentanil use was significantly higher in group S compared to group NS (P = 0.00).
Conclusion: The amount of the anesthetic required to ensure equal anesthetic depth in similar surgeries was higher in active smokers
and passive smokers compared to nonsmokers.
Key words: Smoking, environmental tobacco smoke, anesthetic agent consumption

1. Introduction		
Tobacco smoke consists of more than 4000 particles of
toxic, ciliatoxic, and carcinogenic properties in gas and
particle phases [1,2]. Nonsmokers exposed to secondhand smoke in their environments are described as passive
smokers.
The risk for anesthesia-associated reintubation,
laryngospasm, bronchospasm, aspiration, hypoventilation,
and hypoxemia is 1.8 times greater in smokers compared
to nonsmokers. This rate is 2.3 times higher in younger
smokers and 6.3 times higher in obese smokers. In addition,
the risk of developing bronchospasm is 25.7 times higher
in female smokers than in male smokers [3].
Tobacco smoke induces hepatic microsomal enzymes
and therefore increases the metabolism of drugs such as
phenytoin, chlorpromazine, fentanyl, theophylline, and
others. While it has been shown that the dose requirements
for benzodiazepine increase in smokers, there has been
no change reported in lidocaine and corticosteroids
requirements [2]. In the literature there are limited studies

investigating the anesthetic requirements in patients who
smoke; however, we did not find any studies investigating
the anesthetic requirements for passive smokers. In this
study, we examined the effects of active and passive smoking
on perioperative anesthetic and analgesic consumption.
2. Materials and methods
This study was approved by the ethics committee of İnönü
University Faculty of Medicine and consisted of 90 adult
patients with American Society of Anesthesiologists (ASA)
I-II physical scores and who were scheduled for total
abdominal hysterectomy at the department of obstetrics
and gynecology.
Patients who did not consent to participate, patients
with psychiatric problems, drug or alcohol abusers,
patients who used drugs known to cause hypersensitivity,
and patients with systolic arterial pressure greater than 160
mmHg and diastolic blood pressure greater than 90 mmHg
or heart rates lower than 50 beats/min were excluded from
the study (Figure 1).
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Consort Flow Diagram

Enrollment

Assessed for eligibility (n=95)
Excluded (n=2)
Not meeting inclusion criteria (n=2)
Declined to participate (n=0)
Other reasons (n=0)

Randomized (n=93)

Allocation
Allocated as Smoker
(n=31)

Allocated as Nonsmoker
(n=31)

Allocated as Passive Smoker
(n=31)

Follow-Up

Lost to follow- up unsuitable
specimen for analysis) (n=1)

Lost to follow-up (drug allergy
during induction of anesthesia)
(n=1)

Lost to follow- up unsuitable
specimen for analysis) (n=1)

Analysis

Analyzed (n=30)

Analyzed (n=30)

Analyzed (n=30)

Figure 1. Consort flow diagram of patients.

Patients who fulfilled the criteria for inclusion in the
study were interviewed regarding their history of smoking
and the presence of smokers in their environments one
day before the operation. Patient responses were placed
in a sealed envelope and were not opened until the study
was terminated. Active smoker patients with a history
of smoking 10 cigarettes per day over a period of one
year or longer were placed in group S; passive smoker
patients exposed to cigarette smoke every day for at
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least one year through sharing their environment with
people who smoked daily were placed in group PS; and
patients without a history of smoking or exposure to
smoke were placed in group NS. Various measurements,
such as cotinine, carbon monoxide, and thiocyanate,
can be taken to determine whether a person smokes.
Since carbon monoxide and thiocyanate can be acquired
through environmental sources, their measurement for
the purpose of evaluating tobacco use may give misleading
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results. With active or passive cigarette smoking, nicotine
is absorbed from the lungs and mucous membranes in
the mouth and is immediately metabolized to cotinine in
the body. The cotinine can be detected even several days
after termination of smoking. Therefore, we planned to
analyze the serum cotinine levels in the patients’ blood
in order to eliminate self-report errors. Prior to starting
the operation and after placing the intravenous catheter,
a 3 mL blood sample was collected in order to analyze
serum cotinine levels. The serum samples were stored at
–80 °C until all samples were obtained; all samples were
examined together. Serum cotinine levels were measured
by the competitive micropallets immunoassay method
using a commercially available cotinine kit (Cotinine
EIA, Florence, Italy). Serum cotinine levels >50 ng/mL
indicated that the patient was an active smoker; serum
cotinine levels 11–50 ng/mL indicated that the patient had
recently quit smoking or was a passive smoker; and serum
cotinine levels 1–10 ng/mL indicated that the patient was
a nonsmoker.
Preoperative premedication was not given to any
patient. In the operating room all patients were closely
monitored via ECG (DII), pulse oximetry (SpO2),
noninvasive blood pressure, and body temperature. Then,
a Ringer’s lactate infusion was started. The BIS monitor
(A-2000 Bispectral Index, Aspect Medical Systems, the
Netherlands) was used to assess the depth of anesthesia.
Patient foreheads and temporal regions were cleaned with
alcohol, and the BIS sensor (BIS Quatro, Aspect Medical
Systems, the Netherlands) was placed.
The standard anesthesia technique was applied to all
patients. Thirty seconds after a remifentanil infusion of
0.5 µg/kg/min dose was started, 0.5 mg/kg propofol bolus
was applied. Every 20 s after the bolus dose was given a
verbal warning was issued and an additional dose of 20
mg propofol was given until the response to stimulation
disappeared. Following loss of consciousness, a 75 µg/
kg/min propofol infusion was started. Then, 0.6 mg/
kg atracurium was given, and respiratory support was
provided for 3 min with a face mask. After BIS values ˂45
and adequate muscle relaxation were achieved, patients
were intubated with an endotracheal tube. After intubation,
all patients were continuously mechanically ventilated
using a Dräger Cato edition (Dräger, Germany) anesthesia
machine with a 40% O2–air mixture at intermittent positive
pressure ventilation mode with a tidal volume (6–8 mL/
kg), a respiratory frequency of 10–12 min and end-tidal
CO2 values 30–35 mmHg. The remifentanil infusion rate
was reduced by 50%. The BIS value was kept between 45
and 60 throughout the surgery. BIS, mean arterial blood
pressure (MAP), and heart rate (HR) values were measured
and recorded at the start (t0), before intubation (t1), 5 min
after intubation (t2), intraoperative 10 min (t3), 20 min (t4),

30 min (t5), 40 min (t6), 50 min (t7), 60 min (t8), and prior
to extubation (t9).
An additional 20 mg propofol dose was administered,
and the propofol infusion rate was increased by 50%
when superficial signs of anesthesia (movement and facial
grimacing) were observed or the BIS level was >60.
The remifentanil infusion rate was arranged so
that MAP and HR were ±20% of their starting values.
In cases where hypertension or tachycardia occurred,
administration of 1 µg/kg remifentanil bolus was planned;
if the patient did not respond to that bolus dose after 1
min, an additional bolus dose would be administered. If
hypotension developed, fluid therapy and a 50% reduction
in the rate of infusion of remifentanil were planned. If,
despite this treatment, hypotension could not be corrected,
5 mg of ephedrine would be administered.
All surgical operations were performed in a similar
manner by the same surgical team. After closing the
surgical field, the infusion of propofol and remifentanil
was terminated, and patients were ventilated with 6 L/
min 100% O2. Then, after establishing that adequate
spontaneous breathing and muscle strength were achieved,
patients were extubated.
The primary endpoint of the study was determination
of the total amount of propofol and remifentanil
consumed, while the second endpoint was examination of
perioperative MAP, HR, and BIS values.
3. Results
Demographic characteristics such as age, height, body
weight, ASA, and duration of surgery and anesthesia for
all patients are shown in Table 1. There were no statistically
significant differences between groups in the comparison
of these data (P > 0.05).
The comparison of serum cotinine levels among groups
showed that there was a statistically significant difference
between groups (Table 2).
Moreover, there was a significant difference between
groups in terms of induction and maintenance of
anesthesia and overall amount of consumed propofol and
remifentanil. The amount of propofol used for induction
was significantly higher in group S compared to groups PS
and NS (P < 0.05), and the amount of propofol consumed
by individuals in group PS was also significantly higher
than in group NS (P < 0.05). Analysis of the total
consumption of propofol showed that consumption in
group S was significantly higher compared to groups PS
and NS (P < 0.05), and the amount of propofol consumed
by group PS was significantly higher than in group NS (P
< 0.05). Furthermore, total remifentanil consumption by
group S was significantly higher compared to group NS (P
< 0.05) (Table 3).
Statistically significant changes were observed in the
analysis of hemodynamic data, mean arterial pressure,
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Table 1. Demographic characteristics and duration of anesthesia and surgery (values are presented
as mean ± SD).
Group S
(n = 30)

Group PS
(n = 30)

Group NS
(n = 30)

P-value

Age (year)

45.38 ± 6.77

43.38 ± 11.45

46.63 ± 8.64

0.153

Weight (kg)

70.44 ± 11.64

80.76 ± 25.75

76.66 ± 33.20

0.286

Length (cm)

162.44 ± 4.65

162.26 ± 6.80

162.1 ± 7.30

0.512

Anesthesia time (min)

87.78 ± 20.23

80.76 ± 25.75

76.66 ± 33.20

0.146

Surgery time (min)

73.33 ± 21.42

65.84 ± 23.40

67.83 ± 32.12

0.272

ASA I/II

18/12

18/12

19/11

0.357

SD: Standard deviation
ASA: American Society of Anesthesiologists score
Table 2. Results of cotinine serum levels.
Group S
n (%)

Group PS
n (%)

Group NS
n (%)

Low (1–10 ng/mL)

0 (0)

2 (6.6)

30 (100)

Moderate (11–50 ng/mL)

1 (3.3)

28 (93.3)

0 (0)

High (>50 ng/mL)

29 (96.6)

0 (0)

0 (0)

Values are presented as number and percentage.
Table 3. The consumption of propofol and remifentanil by group (mean ± SD).
Induction propofol
(mg)

Total propofol
(mg)

Induction remifentanil
(μg)

Total remifentanil
(μg)

Group S

102.76 ± 12.97

179.38 ± 34.13

37.17 ± 6.95

1315.10 ± 381.63

Group PS

84.53 ± 16.97*#

150.50 ± 32.77*#

36.17 ± 7.73

1240.70 ± 492.97

Group NS

63.17 ± 17.77*

119.37 ± 40.78*

35.47 ± 6.61

1010.13 ± 417.05*

SD: Standard deviation. P-values compared among groups.
*: P < 0.05 compared with group S
#: P < 0.05 compared with group NS

and heart rate. The mean arterial blood pressure (MAP) in
group S was higher than in group NS at all measurement
times (t0–t9) (P < 0.05). Furthermore, MAP values of group
S were significantly higher than those of group PS at t2, t3,
t6, t8, and t9 (P < 0.05). Meanwhile, the MAP value of group
PS was higher than that of group NS only at t3 (P < 0.05)
(Figure 2).
Heart rate values in group S were higher than those of
group NS at all time points (t0–t9) (P < 0.05). The heart rate
values were also higher in group S compared to group PS
at t1, and t4–t9 time points (P < 0.05). In addition, heart rate
values in group PS were higher than those of group NS at
t1–t6 time points (P < 0.05) (Figure 3).
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4. Discussion
Smoking is a harmful habit that affects individuals and
society by interfering with the treatment of chronic
diseases and causing premature death. The results of our
study show that while the anesthetic need in smokers
was greater than in passive smokers and nonsmokers,
passive smokers needed more anesthetic compared to
nonsmokers. Nonsmokers who passively inhale cigarette
smoke are also exposed to the damage caused by smoking.
There are a very limited number of studies that
investigate anesthetic requirements for smokers. Lysakows
et al. [4] reported that smokers required more propofol
than nonsmokers. Similarly, in our study we determined
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Figure 2. Mean arterial pressure (MAP) in groups. *Group S compared with group NS, # group
S compared with group PS, and group PS compared with group NS.

Figure 3. Patient heart rates (HRs) in groups.

that perioperative total propofol consumption in smokers
was 50% greater compared to nonsmokers and 19% greater
compared to passive smokers.
Cigarette smoke contains chemicals such as
nicotine, carbon monoxide, nitrogen oxides, volatile
aldehydes, hydrogen cyanide toxins, and polycyclic
aromatic hydrocarbons (PAHs). Polycyclic aromatic
hydrocarbons are the most important factor affecting
the liver cytochrome P450 enzyme system (CYP) [5].
The cytochrome P450 enzyme system is the first defense
mechanism against potentially harmful substances that
the body encounters. In humans, approximately 30 CYP
isoenzymes are responsible for drug metabolism; the most
important of these are CYP3A4 and CYP2D6. Many drugs,
including volatile anesthetic agents, are metabolized by
CYP3A4 isoenzyme. However, cigarette smoke interacts
with CYP1A1, CYP1A2, and CYP2E1 enzymes, allowing

the hepatic effects of PAHs to manifest within 3–6 h and
reach the maximum level within 24 h. Increased smoking
leads to a proportional increase in enzyme induction [5].
CYP1A2 which metabolizes drugs such as theophylline,
imipramine, paracetamol, and phenacetin is mainly
localized in the liver and is induced by smoking. Smoking
modifies enzyme activity and leads to an increase in the
theophylline requirement in asthmatic patients and the
haloperidol requirement in psychiatric patients. Polycyclic
aromatic hydrocarbons and nicotine have also been
reported to induce the CYP2E1 enzyme system [5].
UDP-glucuronyl transferase (UGT) is the major
glycoprotein that resides in the membrane of endoplasmic
reticulum. In addition to various environmental factors,
smoking affects the activity of UGT. In humans, there
are approximately 24 variants of UGT gene. The UGT
2B7 subset variant, which plays an important role in the
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metabolism of morphine and codeine, is induced by PAH
in cigarette smoke. The major metabolites of morphine,
morphine-3-glucuronide (M3G) and morphine-6glucuronide (M6G), have 50 times more analgesic
efficacy compared to morphine itself. Cigarette smoke
induces UGT2B7 enzyme, and therefore increases the
requirement for morphine by reducing the formation of
M6G. Similar to morphine, smoking resulted in increased
requirements for dextropropoxyphene and pentazocine in
the perioperative and postoperative periods [5]. Glasson
et al. reported that smoking changed the pain threshold.
The same study also suggested that this change might have
occurred via receptor-mediated UGT enzyme induction
or by affecting liver clearance of morphine [6]. Rogers et
al. [7] administered patients with a standard dose of 60 mg
of codeine, and found that codeine clearance accelerated
in smokers. The analgesic effect of codeine emerges by
conversion to morphine via demethylation mediated by the
CYP2D6 enzyme, and alternatively, through conversion
to its active metabolite, codeine–6-glucuronide, as a
result of demethylation by CYP3A4 enzyme. Morphine
is primarily metabolized to normorphine via UGT and
CYP3A4 enzymes [5]. In addition, Yue et al. [8] showed
that smoking accelerates codeine glucuronidation
without using O- and N-demethylation. Stanley et
al. [9]. reported increased fentanyl consumption and
an associated increase in the frequency of side effects
such as rigidity and hypertension in smoking patients
undergoing coronary artery bypass graft (CABG). Several
investigators in the above studies have connected the
observed increased opioid consumption in smokers with

opioid liver metabolism. Although the remifentanil used
in our study is metabolized independent of the liver, we
saw that consumption was 30% greater in smokers than
nonsmokers, which suggests that there might be different
mechanisms for opioid requirements. In support of this
view, nicotine has been reported to have antianalgesic
effects, suggesting that it may enhance pain perception
in patients. In vitro studies on neuronal physiology have
shown that nicotine increases the transduction in sensory
nerves. On the other hand, in vivo studies have indicated
that nicotine has analgesic effects [10]. Pomerleau [11]
reported increased tolerance to controlled pain stimulus
(cold pressure response) in smokers. Rau et al. [12] tied
the pain relief effect to nicotine and showed that the pain
threshold associated with carotid baroreceptor stimulation
increased proportionally with increasing doses of nicotine.
However, the analgesic effect of nicotine is not fully
understood. Furthermore, a person would have to have
smoked for several years in order for it to affect pain
tolerance; therefore, smoking alone does not explain the
increase of intraoperative analgesia requirements [5].
Limitations of our study included a single-sex study
group consisting of women only. In order to eliminate
variability in anesthetic and analgesic requirements due to
sex differences and surgery type, we limited our study to
female patients undergoing the same type of surgery.
In conclusion, we determined that both active and
passive smokers have higher anesthetic and analgesic
requirements compared to nonsmokers; consequently,
it is necessary to take precautions against possible
complications.
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